Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.

Dervieux T, Weinblatt ME, Kivitz A, Kremer JM.

Ann Rheum Dis. 2013 Jun;72(6):908-10. doi: 10.1136/annrheumdis-2012-202591. Epub 2012 Nov 17.

PMID:
23161901
3.

Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.

Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.

Arthritis Rheum. 2009 Aug;60(8):2248-56. doi: 10.1002/art.24653.

4.

HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis.

Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, Richerson R.

Clin Chem. 2003 Oct;49(10):1632-41.

5.

Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

Dervieux T, Zablocki R, Kremer J.

Rheumatology (Oxford). 2010 Dec;49(12):2337-45. doi: 10.1093/rheumatology/keq216. Epub 2010 Aug 16.

PMID:
20713496
6.
7.

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader RM.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.

PMID:
22152098
8.

Determination of erythrocyte methotrexate polyglutamates by liquid chromatography/tandem mass spectrometry after low-dose methotrexate therapy in Chinese patients with rheumatoid arthritis.

Mo X, Wen Y, Ren B, Chen J, Xu C, Wang X, Huang M, Chen X.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:41-8. doi: 10.1016/j.jchromb.2012.08.032. Epub 2012 Sep 1.

PMID:
22999476
9.

Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.

Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, Smith K, Caldwell J, Furst DE.

Pharmacogenetics. 2004 Nov;14(11):733-9.

PMID:
15564880
10.

A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.

Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J.

J Eur Acad Dermatol Venereol. 2008 Jan;22(1):19-24. Epub 2007 Nov 19.

PMID:
18031504
11.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P.

Gut. 2007 Sep;56(9):1226-31. Epub 2007 Jan 17.

12.

Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.

Pan S, Stamp LK, Duffull SB, Barclay ML, Dalrymple JM, Drake J, Zhang M, Korell J.

Clin Pharmacokinet. 2014 Dec;53(12):1161-70. doi: 10.1007/s40262-014-0179-5.

PMID:
25204405
13.

A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells.

Korell J, Stamp LK, Barclay ML, Dalrymple JM, Drake J, Zhang M, Duffull SB.

Clin Pharmacokinet. 2013 Jun;52(6):475-85. doi: 10.1007/s40262-013-0052-y.

PMID:
23483363
14.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
15.

Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis.

Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML.

Arthritis Rheum. 2008 Nov;58(11):3299-308. doi: 10.1002/art.24034.

16.
17.

Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.

Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, Barclay ML.

Arthritis Rheum. 2010 Feb;62(2):359-68. doi: 10.1002/art.27201.

18.

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.

Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I.

J Rheumatol. 2006 Jan;33(1):37-44.

PMID:
16395748
19.

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P.

J Rheumatol. 2000 Apr;27(4):841-50.

PMID:
10782805
20.

Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.

Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM; iRAMT Study Group..

Curr Med Res Opin. 2005 Aug;21(8):1181-90.

PMID:
16083527

Supplemental Content

Support Center